Physician profile
Tarun Madappa
NPI 1447374699
$174,246.60
in general payments reported to CMS, 2019-2025
33 companies · $63K in 2025
The $63K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $955 · 2021: $1,816 · 2022: $28K · 2023: $36K · 2024: $43K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Travel and Lodging: $16K · Honoraria: $11K · Food and Beverage: $8,862 · Education: $3,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,922.52 |
| Travel and Lodging | $16,273.97 |
| Honoraria | $10,800.00 |
| Food and Beverage | $8,862.16 |
| Education | $3,565.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $92,406.41 | 2019-2024 | Yupelri, Yupelri |
| Viatris Specialty LLC | $45,645.06 | 2025 | Yupelri |
| Verona Pharma, INC. | $13,771.21 | 2025 | Ohtuvayre |
| Intuitive Surgical, INC. | $6,129.87 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $4,467.20 | 2019-2025 | Uptravi, Opsumit |
| Pulmonx Corporation | $4,042.49 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Glaxosmithkline, LLC. | $1,256.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,122.24 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Insmed, INC. | $1,031.25 | 2020-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.40 | 2019-2025 | Ofev |
| United Therapeutics Corporation | $446.88 | 2020-2025 | Tyvaso, Tyvaso |
| Baxter Healthcare | $377.60 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Genzyme Corporation | $351.38 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $340.15 | 2019 | |
| Janssen Pharmaceuticals, INC | $296.19 | 2019-2023 | Xarelto |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $288.26 | 2023-2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $206.04 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $197.80 | 2019-2022 | |
| Melinta Therapeutics, LLC | $195.49 | 2021-2022 | |
| Advanced Respiratory, INC | $149.24 | 2020-2021 | |
| Abiomed | $140.28 | 2023 | Impella |
| Grifols USA, LLC | $139.10 | 2019-2024 | Prolastin-C Liquid |
| Electromed, INC. | $122.59 | 2022-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $118.28 | 2021-2025 | Winrevair |
| Novartis Pharmaceuticals Corporation | $103.88 | 2019 | |
| Philips North America LLC | $86.96 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $76.29 | 2021-2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $66.59 | 2020-2025 | Glassia |
| Chiesi USA, INC. | $61.70 | 2019-2022 | |
| Zoll Respicardia, INC. | $39.37 | 2025 | Remede System |
| Lilly USA, LLC | $21.30 | 2025 | Zepbound |
| Apria Healthcare LLC | $21.21 | 2021 | |
| Veran Medical Technologies, INC. | $17.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Madappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.